Description: <p><b>Linalool</b> — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile, lipophilic phytochemical found in many essential oils, notably lavender, coriander, basil, rosewood, and related aromatic plants. It is formally classified as a small-molecule monoterpenoid and fragrance/flavor compound; common abbreviations are LIN and Lin. Linalool occurs as (R)- and (S)-enantiomers with differing sensory and potentially pharmacological properties. In oncology it should be classified as a preclinical experimental bioactive rather than an established anticancer treatment.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of apoptosis, prominently involving mitochondrial membrane depolarization, Bcl-2-family regulation, cytochrome-c/caspase signaling, and in some models p53/CDKI activation.</li>
<li>Cell-cycle arrest through modulation of cyclins, CDKs, p21, p27, p18 and related checkpoint machinery, with the arrest phase varying by cancer model.</li>
<li>Suppression or remodeling of proliferative survival signaling, particularly PI3K/Akt/mTOR and Ras/MAPK pathways; Akt/ERK responses can become adaptive or pro-survival at high concentrations.</li>
<li>ROS-mediated oxidative cytotoxicity, including hydroxyl-radical generation, lipid peroxidation and mitochondrial injury in selected cancer models; this is dose- and model-dependent rather than a universal linalool mechanism.</li>
<li>Chemosensitization, particularly enhancement of doxorubicin accumulation and cytotoxicity in experimental models, including drug-resistant breast cancer cells.</li>
<li>Suppression of migration, invasion and proliferative phenotype in selected tumor models.</li>
<li>NR3C2 stabilization with NFKBIZ induction and downstream NF-κB suppression in gastric cancer, representing a newer cancer-specific mechanistic axis requiring replication.</li>
<li>PGK1 suppression and PPARγ-associated signaling in breast cancer, currently supported primarily by mechanistic preclinical evidence.</li>
<li>Context-dependent NRF2/redox modulation in normal tissues and tumor-bearing animals; NRF2 activation is better established as a tissue-protective response than as a core direct anticancer mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Linalool is rapidly systemically absorbed after oral administration but undergoes substantial distribution and metabolism. In healthy humans receiving 100 mg orally, mean serum Cmax was approximately 85.5 ng/mL at about 1.15 h, with an apparent half-life of approximately 3.9 h and AUC of approximately 442 h·ng/mL. Its volatility, poor aqueous solubility, rapid metabolism and formulation dependence constrain systemic anticancer exposure. Lipid, cyclodextrin, nanoemulsion and nanoparticle formulations are being investigated to improve delivery.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> There is a major exposure gap. A human 100-mg oral dose produced a Cmax of approximately 85.5 ng/mL, equivalent to roughly 0.55 µM linalool, whereas many anticancer experiments use tens to hundreds of micromolar concentrations and some mechanistic studies use 1–2.5 mM. Thus, many commonly reported direct anticancer concentrations exceed measured human systemic exposure by approximately two to three or more orders of magnitude. Low-micromolar effects reported in a few cell models are more pharmacokinetically interesting but remain unvalidated clinically. Formulation or local-delivery strategies would likely be required to reproduce many experimental exposures.</p>
<p><b>Clinical evidence status:</b> Preclinical. Evidence includes cancer-cell experiments and several rodent/xenograft studies, including prostate, colon, breast, gastric and ovarian cancer models. Human pharmacokinetic data are available, but there is no established human anticancer efficacy evidence and no approved oncology indication for linalool. Human use of linalool-containing essential oils is principally in fragrance, flavor and supportive/aromatherapy contexts rather than tumor treatment.</p>
<h3>Linalool Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis</td>
<td>↓ MMP; ↑ cytochrome c; ↑ caspase-3; ↑ PARP cleavage; ↑ apoptosis</td>
<td>Less pronounced in some comparative models (model-dependent)</td>
<td>R/G</td>
<td>Programmed cancer-cell death</td>
<td>One of the most consistently reproduced anticancer effects across leukemia, liver, oral, prostate, breast and other cancer models.</td>
</tr>
<tr>
<td>2</td>
<td>Cell-cycle checkpoint control</td>
<td>↑ p21; ↑ p27; ↑ p18; ↓ CDK4; ↓ cyclin A; ↑ G0/G1 or G2/M arrest (model-dependent)</td>
<td>Less well characterized</td>
<td>G</td>
<td>Proliferation arrest</td>
<td>Phase of arrest differs among tumor types, so linalool should not be assigned one universal cell-cycle phase.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K Akt mTOR survival signaling</td>
<td>↓ PI3K/Akt signaling at lower experimental concentrations; ↓ mTOR at higher concentrations; ↑ Akt can occur as adaptive signaling (dose-dependent)</td>
<td>Context-dependent</td>
<td>R/G</td>
<td>Reduced survival signaling</td>
<td>Strong mechanistic evidence in selected models, but signaling is biphasic. High-dose Akt activation should not be incorrectly recorded as uniform Akt inhibition.</td>
</tr>
<tr>
<td>4</td>
<td>Oxidative stress and lipid peroxidation</td>
<td>↑ ROS; ↑ hydroxyl radicals; ↑ lipid peroxidation; ↑ apoptosis (dose-dependent)</td>
<td>↔ or ↓ oxidative stress in some normal tissues (model-dependent)</td>
<td>R/G</td>
<td>Selective oxidative cytotoxicity</td>
<td>Colon models demonstrate cancer-selective hydroxyl-radical generation. HepG2 ROS generation was prominent at approximately 2 mM, making exposure highly relevant.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS MAPK stress response</td>
<td>↑ ROS; ↓ MMP; ↑ JNK; ↑ ERK at high concentration (dose-dependent)</td>
<td>Not established</td>
<td>R/G</td>
<td>Stress-mediated apoptosis</td>
<td>ROS scavenging partially prevents mitochondrial depolarization and ERK/JNK activation in HepG2 cells, supporting a causal ROS component.</td>
</tr>
<tr>
<td>6</td>
<td>p53 and CDKI signaling</td>
<td>↑ p53; ↑ p21; ↑ p27; ↑ GADD45α; ↑ JNK</td>
<td>Relative sparing reported in normal hematopoietic cells in one leukemia study</td>
<td>G</td>
<td>Growth arrest and apoptosis</td>
<td>Especially relevant to leukemia models; dependency on functional p53 is not established across all cancers.</td>
</tr>
<tr>
<td>7</td>
<td>Chemosensitization and doxorubicin transport</td>
<td>↑ intracellular doxorubicin; ↑ doxorubicin cytotoxicity; ↓ Bcl-xL</td>
<td>Not adequately established</td>
<td>R/G</td>
<td>Enhanced chemotherapy response</td>
<td>Reported in breast cancer including multidrug-resistant cells and supported by animal combination experiments. This remains preclinical.</td>
</tr>
<tr>
<td>8</td>
<td>NR3C2 NFKBIZ NF-κB signaling</td>
<td>↑ NR3C2 stability; ↑ NFKBIZ; ↓ NF-κB signaling; ↓ proliferation; ↓ migration; ↓ invasion</td>
<td>Not established</td>
<td>G</td>
<td>Growth and invasion suppression</td>
<td>Recent gastric-cancer evidence supports direct interaction with NR3C2 and functional rescue experiments, but independent replication is needed.</td>
</tr>
<tr>
<td>9</td>
<td>PGK1 and PPAR signaling</td>
<td>↓ PGK1; ↑ PPARγ; ↓ proliferation; ↓ migration; ↓ invasion</td>
<td>Not established</td>
<td>G</td>
<td>Metabolic and proliferative suppression</td>
<td>Reported in breast-cancer models. PGK1 binding evidence includes computational methods supplemented by cellular validation; target assignment remains less mature than apoptosis or cell-cycle mechanisms.</td>
</tr>
<tr>
<td>10</td>
<td>NRF2 cytoprotective redox signaling</td>
<td>Context-dependent</td>
<td>↑ NRF2/HO-1 and antioxidant defenses in several injury models</td>
<td>R/G</td>
<td>Normal-tissue protection</td>
<td>Secondary mechanism. NRF2 activation is better supported for protection against oxidative tissue injury than for direct cancer-cell killing and therefore should not be treated as a universal anticancer NRF2 effect.</td>
</tr>
<tr>
<td>11</td>
<td>Migration and invasion</td>
<td>↓ migration; ↓ invasion (model-dependent)</td>
<td>Not established</td>
<td>G</td>
<td>Reduced malignant phenotype</td>
<td>Observed across selected lung, breast and gastric cancer models, often at concentrations substantially above measured human systemic exposure.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental concentrations frequently exceed achievable free systemic exposure</td>
<td>Oxidation products can cause contact sensitization</td>
<td>G</td>
<td>Limits systemic anticancer translation</td>
<td>Human 100 mg oral Cmax is approximately 85.5 ng/mL or 0.55 µM, whereas many cancer studies use approximately 10–1000+ µM. Formulation, local delivery and tumor exposure therefore remain major translational issues.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>